Cholesterol pill boosts cancer immunotherapy

Studies in mice suggest that tweaking cholesterol levels with avasimibe, a lipid-lowering drug, may boost the effectiveness of new immunotherapy drugs, such as nivolumab (Opdivo) and pembrolizumab (Keytruda). Adding avasimibe to PD-1 inhibitors improved tumour inhibition and increased survival in mice. Read more here.

read more

Non-aspirin NSAIDs associated with kidney cancer

A study presented at the 2016 Genitourinary Cancers Symposium last week warns that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen but not aspirin or acetaminophen (Tylenol), appear to be associated with fatal cases of renal cell carcinoma (RCC). The data from the study suggest that non-aspirin NSAID use is associated with an […]

read more

Relapse of RCC can be possible years after initial treatment

A recent study published in Oncology Times by a group of researchers based in New Orleans, USA, has shown that renal cell carcinoma (RCC) may return years after successful treatment. In the study, 502 patients who were clear of cancer for at least 10 years were followed for late recurrences. Eight (8) patients had a […]

read more

Children’s kidney cancer diagnosed later in UK than Germany

In a recent study by Cancer Research UK and published in Archives of Disease in Childhood last week, Wilms’ tumours where diagnosed in the UK at a later and more advanced stage than those diagnosed in Germany. Wilms’ tumour is the most common form of childhood kidney cancer, affecting about 80 children a year in […]

read more

Adjuvant sunitinib or sorafenib for high risk kidney cancer

A study published in The Lancet last week reported that adjuvant treatment (treatment following surgery) with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase 3 study. Furthermore, substantial treatment discontinuation occurred because of excessive toxicity, despite dose reductions. These results provide a strong […]

read more

Christy Watson talks about renal cancer

Christy talks about her experience and why she’s hosting her 3rd Green Ribbon Ball – she’s raised more than £75,000 for the charity. Get in touch at Renal Cancer Research Fund, Scotland. During the interview, Christy talks about her experience of being on a kidney cancer clinical trial, symptoms of kidney cancer, and the reason for starting […]

read more

Largest genomic study of kidney cancer

  Researchers in America have recently completed a study that analysed close to 900 kidney cancers at the molecular level. The team discovered that what have historically been considered three major types of kidney cancer according to their characteristics under the microscope (clear cell, papillary and chromophobe), could be further classified into nine major subtypes through molecular […]

read more

Be Clear on Cancer “Blood in Pee” Campaign

NHS England’s Be Clear on Cancer ‘Blood in Pee’ campaign was launched on 15 February 2016. The campaign will run for almost seven weeks across England with the aim of raising awareness of a key symptom of both bladder and kidney cancers – blood in pee. The campaign encourages people who notice blood in their pee to […]

read more
Showing 811 to 818 of 818 results
  TOP